Fenebrutinib for treating relapsing multiple sclerosis [ID6577]
Awaiting development
Reference number: GID-TA11775
Expected publication date: TBC
As you will be aware, the Department for Health & Social Care has asked NICE to conduct an appraisal of fenebrutinib within its marketing authorisation for treating relapsing multiple sclerosis.
Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during late August 2026 when we will write to you about how you can get involved.